logo
Stock futures are little changed after market returns to record highs: Live updates

Stock futures are little changed after market returns to record highs: Live updates

CNBC3 days ago
Traders work at the New York Stock Exchange on August 12, 2025.
NYSE
Stock futures are little changed Tuesday night as investors look ahead to inflation data due later this week.
Futures tied to the Dow Jones Industrial Average dropped 13 points, or less than 0.1%. S&P futures fell 0.04%, while Nasdaq 100 futures were 0.02% lower.
In after-hours trading, Cava shares plunged more than 22% after the Mediterranean restaurant chain reported disappointing second-quarter revenue growth and lowered its same-store sales forecast for the full year. CoreWeave shares dropped about 5% even though the artificial intelligence infrastructure provider delivered a top-line beat and said its revenue more than tripled from a year earlier.
The major U.S. indexes are coming off of a strong trading session, which saw the S&P 500 and tech-heavy Nasdaq Composite close at fresh record highs. The S&P 500 added 1.1% to settle at 6,445.76, while the Nasdaq ended 1.4% higher at 21,681.90. The Dow Jones Industrial Average added about 483 points, or 1.1%, to close at 44,458.61.
The Russell 2000 Index jumped nearly 3% during the session as small-cap stocks are generally considered a beneficiary of lower short-term borrowing rates.
Stocks traded higher Tuesday as inflation data was tamer than expected, soothing investor fears that tariffs are not spiking prices. Traders are now pricing in a nearly 94% chance of a rate cut at the Federal Reserve's September meeting, per trading data from the CME's FedWatch Tool.
Thursday's producer price index report on wholesale inflation will add another piece of the economic picture. The report comes ahead of the Fed's Jackson Hole meeting on Aug. 21-23, which could also help shape expectations for the central bank's next policy move.
Not all investors came away convinced by Tuesday's strong moves. 3Fourteen Research co-founder Warren Pies said the moves in small-cap names may not be what they seem in this late-cycle environment.
"We've had some seasonal buying in the beginning of August, and I think people are starting to jump the gun and misinterpret that as this summer melt-up that every wants to believe in," Pies said on CNBC's "Closing Bell." "I think there is some concerns in my mind about the labor market and the growth story and the market's kind of glossing over them."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

Yahoo

time3 minutes ago

  • Yahoo

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They are also worried about the patent expiration of the firm's mega cancer drug KEYTRUDA and wondering whether Merck & Co., Inc. (NYSE:MRK) will be able to follow up with an equally successful successor. However, the shares did gain 3% this week after Pfizer announced that its bladder cancer drug PADCEV improves survival rates when paired with KEYTRUDA. Cramer was impressed as he commented: 'Look at Merck. I mean, Saint Merck. What a tough, what a tough.' Photo by National Cancer Institute on Unsplash Here are his earlier comments about Merck & Co., Inc. (NYSE:MRK): 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Salesforce, Inc. (CRM)'s CEO Is Pushing Back Against The AI Vs Enterprise Software Narrative, Says Jim Cramer
Salesforce, Inc. (CRM)'s CEO Is Pushing Back Against The AI Vs Enterprise Software Narrative, Says Jim Cramer

Yahoo

time3 minutes ago

  • Yahoo

Salesforce, Inc. (CRM)'s CEO Is Pushing Back Against The AI Vs Enterprise Software Narrative, Says Jim Cramer

We recently published . Salesforce, Inc. (NYSE:CRM) is one of the stocks Jim Cramer recently discussed. Salesforce, Inc. (NYSE:CRM)'s shares have lost 28% year-to-date as the firm has struggled to retain investor attention in the age of AI. Like investors are hawkishly watching its revenue pipeline and revenue commitments for the rest of the year – a fact which led the stock to dip 5% in May after its fiscal first quarter earnings. Cramer discussed the sentiment surrounding enterprise software stocks and CEO Marc Benioff's attempts to counter it: '. . .and I think that people should recognize that these companies are all being viewed as, let's say carrion, because what's happened is this that you can develop your own stuff that is better. Now Marc Benioff is doing some pushback on that by the way, he's saying that if you're doing process stuff, you're not going to be able to, maybe creative, that would be Adobe. But not, Salesforce. So Marc's pushing back Salesforce. . .' Pixabay/Public Domain Here are his previous remarks about Salesforce, Inc. (NYSE:CRM): 'Okay, so Salesforce is a little tough right now because right now, the enterprise software companies are all coming down. I have not been recommending the stock hard. I want to see what happens with the quarter. I wish I could be more definite, but sometimes it's better just to say I don't have a handle on it.' While we acknowledge the potential of CRM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer
Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

Yahoo

time3 minutes ago

  • Yahoo

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

We recently published . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)'s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck's well-known cancer treatment, KEYTRUDA. The gains were a much-needed boost to the stock, which is still down by 5.6% year-to-date, as the firm has struggled to grow revenue in a turnaround effort led by CEO Albert Bourla. Cramer lamented that Pfizer Inc. (NYSE:PFE)'s stock didn't move higher on the news: 'Bladder cancer. Now that is left over from the Seagen. The Seagen deal, that was supposed to be very, very important. They spent a fortune on Seagen. And I thought the [inaudible] I thought would be a little more just positive. People are not buying the stock. People just feel like, Pfizer comes up with good thing, good thing, good thing, and no one seems to, David, take it as gospel.' Copyright: kadmy / 123RF Stock Photo Cramer discussed Pfizer Inc. (NYSE:PFE) ahead of its earnings: 'There's another one, that I'm not so sure of, reporting at the same time, though, Pfizer. We need to see some really dramatic results here from the clinical trials like the ones that Pfizer picked up when they bought the Seagen at the end of 2023. It's enough time to see more than we've seen already, I gotta tell you that. And they better hurry up because the shareholder base is getting very restive, and who knows what the president has… against this industry.' While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store